Does Tirzepatide Cause Thyroid Cancer?
No, tirzepatide has not been shown to cause thyroid cancer in humans, though it carries a contraindication for patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) based on preclinical rodent studies. 1
The Evidence in Humans
The concern about thyroid cancer with tirzepatide stems from animal studies, not human data. Here's what we know:
Preclinical vs. Clinical Data
- Rodent studies showed thyroid C-cell hyperplasia, adenomas, and medullary thyroid carcinomas with GLP-1 receptor agonists (the class tirzepatide belongs to) 1
- Human studies show no evidence of increased calcitonin or C-cell neoplasia 1
- Critical biological difference: Human thyroid C-cells do not express GLP-1 receptors the way rodent C-cells do 1
Clinical Trial Evidence
Multiple meta-analyses examining incretin-based therapies (including tirzepatide) found:
- No increased risk for thyroid cancer with GLP-1 receptor agonists or DPP-4 inhibitors in humans 1
- A 2025 meta-analysis of 13 RCTs with 13,761 participants found identical cancer risk between tirzepatide and control groups over 26-72 weeks (risk ratio 0.78; 95% CI 0.53-1.16) 2
- No cases of papillary thyroid carcinoma were reported despite increases in serum calcitonin with higher tirzepatide doses 2
- A 2024 meta-analysis of 9 RCTs confirmed tirzepatide does not increase risk for any cancer type 3
Real-World Surveillance Data: A Critical Caveat
Post-marketing surveillance data presents a more complex picture:
- FDA Adverse Event Reporting System (FAERS) analysis showed a disproportionate reporting signal for medullary thyroid cancer with tirzepatide (ROR 13.67; 95% CI 4.35-42.96) 4
- Another FAERS analysis found positive signals for thyroid mass and medullary thyroid carcinoma 5
- A 2025 FAERS study showed significant associations between GLP-1 receptor agonists and thyroid cancer reports, including tirzepatide (ROR 2.09; 95% CI 1.51-2.89) 6
However, these surveillance findings must be interpreted cautiously:
- FAERS data reflects reporting bias, not causation
- The signal may represent heightened awareness and reporting rather than true increased risk
- Clinical trial data with controlled follow-up shows no increased risk 2, 3
Clinical Recommendations
Absolute Contraindications
Do not prescribe tirzepatide to patients with: 1, 7
- Personal history of medullary thyroid carcinoma
- Family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Genetic testing positive for MEN 2
Monitoring
- The FDA explicitly states that routine monitoring for medullary thyroid carcinoma (e.g., calcitonin levels) is not needed in patients taking GLP-1 receptor agonists 1
- This applies to tirzepatide as well
Patient Counseling
Inform patients about:
- The theoretical risk based on animal studies
- The absence of evidence for increased risk in humans
- The absolute contraindications listed above
- Symptoms warranting evaluation (neck mass, hoarseness, dysphagia)
Bottom Line
The weight of evidence from controlled clinical trials demonstrates that tirzepatide does not cause thyroid cancer in humans. The contraindication exists out of regulatory caution based on rodent data and the biological plausibility in patients with specific genetic predispositions (MEN 2) or pre-existing MTC. For the general population without these risk factors, thyroid cancer should not be a barrier to prescribing tirzepatide when clinically indicated for diabetes or obesity management.
Human C-cells lack the GLP-1 receptor expression seen in rodents, providing a mechanistic explanation for why the rodent findings don't translate to humans 1. The FAERS signals likely reflect reporting bias rather than true causation, as they contradict the controlled trial evidence.